Abemaciclib With HR+, HER2+ Advanced or Metastatic breast

The primary objective of this study is to compare the efficacy of abemaciclib plus trastuzumab plus fulvestrant and abemaciclib plus trastuzumab to standard-of-care single-agent chemotherapy of physician’s choice plus trastuzumab with respect to progression free survival (PFS).

August 09, 2017